» Articles » PMID: 34774556

Dephosphorylation of AMP-activated Protein Kinase Exacerbates Ischemia/reperfusion-induced Acute Kidney Injury Via Mitochondrial Dysfunction

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2021 Nov 14
PMID 34774556
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Kidney tubular epithelial cells are high energy-consuming epithelial cells that depend mainly on fatty acid oxidation for an energy supply. AMP-activated protein kinase (AMPK) is a key regulator of energy production in most cells, but the function of AMPK in tubular epithelial cells in acute kidney disease is unclear. Here, we found a rapid decrease in Thr172-AMPKα phosphorylation after ischemia/reperfusion in both in vivo and in vitro models. Mice with kidney tubular epithelial cell-specific AMPKα deletion exhibited exacerbated kidney impairment and apoptosis of tubular epithelial cells after ischemia/reperfusion. AMPKα deficiency was accompanied by the accumulation of lipid droplets in the kidney tubules and the elevation of ceramides and free fatty acid levels following ischemia/reperfusion injury. Mechanistically, ischemia/reperfusion triggered ceramide production and activated protein phosphatase PP2A, which dephosphorylated Thr172-AMPKα. Decreased AMPK activity repressed serine/threonine kinase ULK1-mediated autophagy and impeded clearance of the dysfunctional mitochondria. Targeting the PP2A-AMPK axis by the allosteric AMPK activator C24 restored fatty acid oxidation and reduced tubular cell apoptosis during ischemia/reperfusion-induced injury, by antagonizing PP2A dephosphorylation and promoting the mitophagy process. Thus, our study reveals that AMPKα plays an important role in protecting against tubular epithelial cell injury in ischemia/reperfusion-induced acute kidney injury. Hence, activation of AMPK could be a potential therapeutic strategy for acute kidney injury treatment.

Citing Articles

Annexin A's Life in Pan-Cancer: Especially in Glioma Immune Cells.

Wen Y, Zhou W, Zhao Z, Ma D, Mao J, Cai Y Neuromolecular Med. 2025; 27(1):17.

PMID: 40011350 DOI: 10.1007/s12017-024-08827-9.


UHRF1 promotes calcium oxalate-induced renal fibrosis by renal lipid deposition via bridging AMPK dephosphorylation.

Sun Y, Li B, Song B, Xia Y, Ye Z, Lin F Cell Biol Toxicol. 2025; 41(1):39.

PMID: 39899077 PMC: 11790803. DOI: 10.1007/s10565-025-09991-9.


Lipidomics-based natural products for chronic kidney disease treatment.

Zhang R, Wang J, Wu C, Wang L, Liu P, Li P Heliyon. 2025; 11(1):e41620.

PMID: 39866478 PMC: 11758422. DOI: 10.1016/j.heliyon.2024.e41620.


Dietary or pharmacological inhibition of insulin-like growth factor-1 protects from renal ischemia-reperfusion injury in mice.

Lyon A, Agius T, MacArthur M, Kiesworo K, Stavart L, Allagnat F iScience. 2025; 27(12):111256.

PMID: 39759002 PMC: 11700642. DOI: 10.1016/j.isci.2024.111256.


ATGL regulates renal fibrosis by reprogramming lipid metabolism during the transition from AKI to CKD.

Li X, Chen J, Li J, Zhang Y, Xia J, Du H Mol Ther. 2025; 33(2):805-822.

PMID: 39748508 PMC: 11853023. DOI: 10.1016/j.ymthe.2024.12.053.